Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Georgiamune Inc
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for GIM-531](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GIM531-CT01 | P2 |
Recruiting |
Melanoma |
2025-12-01 |